Ebb & Flow Focus

Actelion Ltd. (SWX:ATLN) shed $615 million in market value last week, despite reporting that 2006 EPS jumped 85%, as investors apparently have some concerns about what’s ahead for the company.

Revenues and EPS have been driven by Tracleer bosentan for pulmonary arterial hypertension. But as Tracleer growth slows, the company’s earnings growth is doing the same, even without potential upcoming competition

Read the full 619 word article

User Sign In